Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.53 |
| ▸ | GSK3B | P49841 | 6/20 | 0.47 |
| ▸ | AXL | P30530 | 2/20 | 0.43 |
| ▸ | MERTK | Q12866 | 2/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5457524 | 0.91 | GSK3B (0.46) | MAPK14GSK3BAXLMERTKMAPK10 | |
| SCHEMBL5452937 | 0.90 | MAPK14 (0.52) | MAPK14GSK3BAXLMERTKMAPK10 | |
| SCHEMBL5460142 | 0.89 | GSK3B (0.45) | MAPK14GSK3BAXLMERTKMAPK10 | |
| SCHEMBL5875486 | 0.89 | GSK3B (0.45) | MAPK14GSK3BAXLMERTKMAPK10 | |
| SCHEMBL5452168 | 0.89 | GSK3B (0.45) | MAPK14GSK3BAXLMERTKMAPK10 | |
| SCHEMBL5462435 | 0.88 | GSK3B (0.44) | MAPK14GSK3BAXLMERTKMAPK10 | |
| SCHEMBL5875557 | 0.87 | GSK3B (0.44) | MAPK14GSK3BAXLMERTKMAPK10 | |
| SCHEMBL5464066 | 0.87 | GSK3B (0.43) | MAPK14GSK3BAXLMERTKMAPK10 | |
| SCHEMBL5875483 | 0.86 | MAPK14 (0.50) | MAPK14GSK3BAXLMERTKMAPK10 | |
| SCHEMBL5460085 | 0.85 | MAPK14 (0.42) | MAPK14GSK3BAXLMERTKMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034030-B2 | Pyralopyridines, process for their preparation and use as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-7034030-B2 | Pyralopyridines, process for their preparation and use as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060058319-A1 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | ALBERTI MICHAEL J | 2006-03-16 | — | — | US | disclosed |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058319-A1 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | CYP3A5, CYP3A4, CYP3A7 | MAPK14 2256/4885GSK3B 2419/4885AXL 2534/4885 |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | QDPR, DPYD, ENTPD5 | MAPK14 1551/4885GSK3B 3047/4885AXL 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.